What is the current stock price of Galectin Therapeutics Inc. (GALT)?

As of the latest market data, Galectin Therapeutics Inc. (GALT) is trading at $2.30. The stock has seen a loss of -5.35% today.

Does Galectin Therapeutics Inc. (GALT) pay a dividend?

Based on current data, Galectin Therapeutics Inc. does not have a confirmed active dividend policy.

What is the market cap of Galectin Therapeutics Inc.?

The current market capitalization of Galectin Therapeutics Inc. (GALT) is approximately unavailable.

GALT

Galectin Therapeutics Inc.·Healthcare

2.30

5.350%(−0.13)

Market Closed

Last Updated: — ET

52W L: $1.2152W H: $7.13

GALT NEWS

zacks.com

Apr 3

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

defenseworld.net

Mar 27

Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk. Volatility and Risk Phio Pharmaceuticals has a

defenseworld.net

Mar 27

Contrasting Galectin Therapeutics (NASDAQ:GALT) & Context Therapeutics (NASDAQ:CNTX)

Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Risk and Volatility Galectin Therapeutics has a

seekingalpha.com

Mar 10

Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript

prnewswire.com

Jan 22

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

newsfilecorp.com

Jan 19

Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud

New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Galectin Therapeutics Inc. (NASDAQ: GALT) ("Galectin Therapeutics Inc.") concerning potential violations of the federal securities laws. Galectin issued a press release on December 19, 2025, "announc[ing] that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted Type C meeting request regarding the development program for belapectin, its investigational galectin-3 inhibitor.

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2002-09-04

Beta

1.04

Websitegalectintherapeutics.com↗